Peking University Cancer Hospital & Institute: Lung Neoplasms trials

The registry lists 18 Lung Neoplasms studies with Peking University Cancer Hospital & Institute as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 2 10No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
• 5T4 Targeting Nanobody Probe for PET Imaging in Solid TumorsNot yet recruitingNCT07589101Not applicable
• PD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNot yet recruitingNCT07442292
• Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATSNot yet recruitingNCT07177924Not applicable
• Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung CancerNot yet recruitingNCT07004712Phase 2
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerRecruitingNCT06926179
• Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsyRecruitingNCT06869239
• Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLCRecruitingNCT06849167Phase 2
• Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06784206Phase 2
• A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical SurgeryRecruitingNCT06674252Not applicable
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLCStatus unknownNCT04629027
• Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
• Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT04137588
• Anlotinib in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03732846Phase 2
• Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung CancerCompletedNCT03113851Phase 2
• Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)Status unknownNCT02179528Phase 2